100 Countries and Regions Grant Use Approval to BIBP’s COVID-19 Vaccine to Support Global Fight Against COVID-19

On August 23 local time, the Technical Review Committee of Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) approved the Inactivated COVID-19 Vaccine (Vero Cell) developed and produced by Beijing Institute of Biological Products Co., Ltd. (BIBP), China National Biotec Group Company Limited (CNBG), Sinopharm (hereinafter referred to as “BIBP’s COVID-19 vaccine”) for emergency use after discussion, and agreed to grant it the approval for emergency use and registration. To date, BIBP’s COVID-19 vaccine has been approved for use in 100 countries and regions.

      COFEPRIS is a highly regulated official drug approval agency of Mexico, and also a member of the PIC/S.

      So far, BIBP’s COVID-19 vaccine has obtained registration approval in nine countries (China, the UAE, Bahrain, Bolivia, Seychelles, Thailand, Turkmenistan, Malaysia and Peru), and market access approval in 8 PIC/S member states (Hungary, Iran, Argentina, Indonesia, Thailand, Malaysia, Singapore and Mexico).